McLeod Health

Place Sticker Here

Bezlotoxumab (Zinplava) Treatment Plan Patient Name: ______ DOB: _____ Weight (kg): ______ Allergies: _____ Appropriate use criteria: The patient must meet ALL below criteria to be considered eligible for bezlotoxumab ☐ At least 18 years of age ☐ Receiving Clostridioides difficile treatment with either fidaxomicin or oral vancomycin ☐ Has had at least 2 previous episodes of *C. difficile* infection (CDI) with most recent episode in the previous 6 months OR this is the patient's first episode of CDI and they have at least 1 risk factor for recurrent infection (risk factors for recurrence: age \geq 65 years, immunocompromised, or severe CDI as defined as WBC > 15,000 OR SCr \geq 1.5 mg/dL) Diagnosis (select one ICD-10 code): ☐ A04.71 Enterocolitis due to *C. difficile*, recurrent ☐ A04.71 Enterocolitis due to *C. difficile*, not specified as recurrent ☐ Other ICD 10 Code: _____ Diagnosis Description: ____ **Drug Orders:** • Bezlotoxumab (Zinplava) (J0565) in 0.9% sodium chloride IV to infuse over 60 minutes through a low sorb 0.22 micron in-line filter Dose: ☐ 10 mg/kg (actual body weight) x 1 dose Use 100 mL NS for doses < 250 mg, 250 mL NS for 250-2,500 mg, and 500 mL NS for > 2,500 mg Lab Orders: ☐ Basic metabolic panel (BMP) □ NT-pro B-Type Natriuretic Peptide (BNP) **Standing Orders:** • Infusion Reaction Protocol (CPOE-1396) will be activated if any hypersensitivity reaction occurs, including anaphylaxis. Infusion will be stopped and physician notified. Physician Signature: _____ Date: _____ Physician Name: ______ Phone: _____

Approved: 07/2021

Insurance/Authorization Information:

Insurance Type:	
Insurance Authorization Reference Number:	
Date Obtained:	_ Authorization Valid Until:
Additional Notes:	

Fax completed Treatment Plan with authorization information to McLeod Infusion Services at the number below or call with any questions.

Florence: 843-777-6001 (Fax)

843-777-4655 (Phone)